The blastomycosis treatment market, projected to be valued at USD 216.3 Million in 2025, is anticipated to grow steadily, reaching USD 349.6 Million by 2032 at a CAGR of 7.1% during the forecast period. This growth is driven by the rising incidence of blastomycosis infections, particularly in endemic regions such as North America, and increasing awareness among healthcare providers regarding early diagnosis and antifungal treatment protocols. Advancements in systemic antifungal therapies, including the use of azoles and amphotericin B formulations, are enhancing treatment outcomes. Additionally, the growing availability of diagnostic tools and improved surveillance efforts by public health agencies are contributing to earlier intervention and better disease management, further supporting the market expansion.

Market Takeaways

• By Treatment Type, Itraconazole is projected to dominate the blastomycosis treatment market with a 58.3% share in 2025. Its dominance is attributed to its well-established clinical efficacy in treating mild to moderate cases of blastomycosis, favorable safety profile, oral administration convenience, and widespread physician preference for long-term outpatient therapy.
• Regionally, North America is expected to lead the blastomycosis treatment market in 2025, driven by the high disease prevalence in endemic areas such as the Mississippi and Ohio River valleys, strong diagnostic infrastructure, and access to advanced antifungal therapies. Increased physician awareness and CDC-supported surveillance programs further strengthen regional market leadership.

Blastomycosis Treatment Market Report Coverage

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/blastomycosis-treatment-market

Market Dynamics

The blastomycosis treatment market is experiencing steady growth, driven by rising disease incidence in endemic regions, improved diagnostic capabilities, and increasing awareness among healthcare professionals. Blastomycosis, a potentially serious fungal infection caused by Blastomyces species, is most prevalent in North America, particularly around the Mississippi and Ohio River valleys. While historically underdiagnosed, growing awareness and enhanced fungal culture and antigen detection methods are improving early detection and treatment outcomes.

The demand for effective antifungal agents, particularly azoles such as itraconazole and newer formulations of amphotericin B, is rising due to their proven efficacy in both pulmonary and disseminated blastomycosis cases. Itraconazole remains the preferred first-line therapy for mild to moderate infections due to its favorable safety profile, while liposomal amphotericin B is reserved for severe or CNS-involved cases.

A February 2024 CDC report using insurance claims data revealed an annual average incidence of 1.8 cases per 100,000 in Vermont, with hospitalization rates between 57–69% and mortality rates of 8–22%. Another CDC report from April 2024 noted U.S. mortality among hospitalized patients usually ranges from 8–10%, spiking to 17% in 2021, signaling underdiagnosis and increased clinical severity.

Additionally, regulatory bodies like the U.S. FDA are increasingly prioritizing fungal disease treatments under antimicrobial resistance initiatives. With more attention to mycoses in both immunocompromised and healthy populations, and with climate change potentially expanding the endemic range, the market is expected to benefit from accelerated research, diagnostic tool development, and broader access to treatment in the coming years.

Market Trends

• Advancements in Liposomal Amphotericin B and Expanded Use in Severe Cases

There is a growing preference for liposomal formulations of amphotericin B in the treatment of severe or disseminated blastomycosis due to their improved safety profile and reduced nephrotoxicity compared to conventional amphotericin B deoxycholate. These formulations are becoming the standard of care for patients with CNS involvement, immunocompromised conditions, or those unable to tolerate azoles.

A landmark case reported in November 2023 by the National Center for Biotechnology Information (NCBI) detailed a 22-year-old patient with disseminated blastomycosis affecting the lungs, pleura, ribs, vertebrae, pericardium, and mitral valve. The patient was successfully treated with a 4-week induction course of liposomal amphotericin B, followed by oral itraconazole. The regimen resulted in complete clinical and laboratory recovery, underscoring the critical role of L-AmB in managing complex, multi-system blastomycosis.

• Improved Diagnostics Driving Early Detection and Targeted Therapy

Recent advancements in fungal diagnostics—including antigen detection assays, PCR-based methods, and imaging techniques—are facilitating earlier identification of blastomycosis, enabling timely and more targeted antifungal treatment. Urine antigen tests and chest CT scans are increasingly being integrated into frontline diagnostic protocols in endemic regions.

In February 2021, researchers developed a TaqMan real-time PCR assay capable of differentiating Blastomyces dermatitidis and B. gilchristii. Validated against cultures and patient specimens, this method enhances laboratory-level accuracy for both outbreak analysis and targeted clinical diagnostics.

Market Opportunities

• Expansion into Underserved and Emerging Endemic Regions

Blastomycosis remains significantly underdiagnosed and undertreated in many rural and underserved areas across North America, particularly in regions surrounding the Mississippi, Ohio, and St. Lawrence River valleys, as well as emerging hotspots in parts of Canada. Limited access to advanced diagnostics and specialist care, along with a lack of awareness among frontline providers, continue to hinder timely diagnosis and treatment.

In January 2023, a review published by the National Library of Medicine in Blastomycosis: A Review of Mycological and Clinical Aspects highlighted SUBA‑itraconazole, a novel formulation with significantly enhanced gastrointestinal absorption. Clinical data indicated that 130 mg administered twice daily provides higher serum concentrations compared to conventional itraconazole (200 mg BID), without added toxicity. This positions SUBA‑itraconazole as a promising and better-tolerated option for outpatient management of blastomycosis.

• Development of Safer, Targeted Antifungal Therapies and Formulations

There is a growing opportunity for pharmaceutical developers to create next-generation antifungal treatments that combine potent efficacy with enhanced safety profiles and simplified dosing regimens. Current reliance on itraconazole and amphotericin B—while effective—is limited by side effects such as hepatotoxicity and nephrotoxicity, which can complicate long-term management, especially in immunocompromised or elderly patients.

According to PubMed in July 2024, SUBA‑itraconazole was officially FDA-approved for blastomycosis and other systemic fungal infections. Thanks to its polymer-matrix design, it overcomes absorption issues and allows consistent serum levels without increased toxicity.

Analyst View

• The blastomycosis treatment market is gaining momentum amid rising case detection across endemic zones in North America and expanding surveillance efforts by public health agencies. Historically underrecognized, the disease is now garnering more attention due to improved diagnostic tools, climate-driven spread, and increased physician awareness, especially in rural and underserved communities.
• The treatment paradigm is evolving with the emergence of safer and more targeted antifungal formulations. SUBA‑itraconazole, now FDA-approved, offers a significant improvement over conventional itraconazole by delivering consistent serum levels with fewer side effects. Additionally, liposomal amphotericin B has become the preferred choice in severe or CNS-involved cases due to its superior safety profile over traditional formulations.
• There is a growing call for therapeutic innovation, especially for immunocompromised patients who often face complex treatment challenges. Next-generation azoles and oral amphotericin B formulations (e.g., encochleated AmB) under development represent strategic opportunities for pharma companies aiming to reduce toxicity, enhance patient compliance, and support outpatient treatment models.
• Looking ahead, the market is poised to benefit from cross-sector collaboration between pharmaceutical developers, diagnostic innovators, and public health bodies. As diagnostic capabilities continue to improve and treatment options diversify, the blastomycosis treatment market is expected to transition toward a more accessible, patient-centered, and resilient ecosystem, capable of managing both endemic and emerging fungal threats with greater precision and efficiency.

Recent Key Developments

• In May 2025, SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, announced that patient dosing has resumed in the Phase 3 MARIO study, which is an innovative study to investigate oral ibrexafungerp as a potential step-down antifungal therapy following IV echinocandin for invasive candidiasis, a life-threatening infection.

Competitive Landscape

• Janssen
• Scynexis Inc
• Novartis AG
• Marck & Co., Inc.
• Sun Pharmaceutical Industries Ltd

Blastomycosis Treatment Market Segmentation

• By Treatment Type
  • Itraconazole
  • Amphotericin B
• Regional Insights
  • North America
    • U.S.
    • Canada
  • Latin America
    • Mexico
    • Brazil
    • Argentina
    • Rest of Latin America
  • Europe
    • Italy
    • Germany
    • U.K.
    • Spain
    • France
    • Russia
    • Rest of Europe
  • Asia Pacific
    • South Korea
    • India
    • Japan
    • China
    • Australia
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa